The Technical Analyst
Select Language :
PT Tempo Scan Pacific Tbk [TSPC.JK]

Exchange: JKT Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic

PT Tempo Scan Pacific Tbk Price, Forecast, Insider, Ratings, Fundamentals & Signals

PT Tempo Scan Pacific Tbk is listed at the  Exchange

-0.50% IDR1 990.00

America/New_York / 3 mai 2024 @ 05:14


PT Tempo Scan Pacific Tbk: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 8 974 621 mill
EPS: 225.07
P/E: 8.84
Earnings Date: Apr 30, 2024
SharesOutstanding: 4 509.86 mill
Avg Daily Volume: 2.34 mill
RATING 2024-05-03
A-
Buy
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Buy
Return On Asset: Buy
DE: Neutral
P/E: Neutral
Price To Book: Sell
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.13x
Company: PE 8.84 | sector: PE 65.62
PE RATIO: COMPANY / INDUSTRY
0.55x
Company: PE 8.84 | industry: PE 16.03
DISCOUNTED CASH FLOW VALUE
IDR3 995.03
(100.76%) IDR2 005.03
Date: 2024-05-05
Expected Trading Range (DAY)

IDR 1 949.32 - 2 030.68

( +/- 2.04%)
ATR Model: 14 days

Live Trading Signals (every 1 min)

Forecast 1: 15:06 - IDR1 980.91
Forecast 2: 15:56 - IDR1 981.50
Forecast 3: 16:00 - IDR1 980.00
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price IDR1 990.00 (-0.50% )
Volume 1.983 mill
Avg. Vol. 2.34 mill
% of Avg. Vol 84.68 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for PT Tempo Scan Pacific Tbk

Last 12 Months

Last 12 months chart data with high, low, open and close for PT Tempo Scan Pacific Tbk

RSI

Intraday RSI14 chart for PT Tempo Scan Pacific Tbk

Last 10 Buy & Sell Signals For TSPC.JK

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            PT Tempo Scan Pacific Tbk

TSPC.JK

PT Tempo Scan Pacific Tbk engages in the pharmaceuticals, personal care and cosmetics, and distribution services businesses in Indonesia and internationally. The company operates through three segments: Pharmaceuticals, Consumer Products and Cosmetics, and Distribution Services. It is involved in the pharmaceutical and medical devices trading; manufacture of soaps, herbal products, powder milk, food and beverages, and plastic packaging; and manufacturing and trading of consumer products, cosmetics, and household products. The company sells its products under the Bodrex, Oskadon, Neo rheumacyl, Bodrexin, Contrexyn, Contrex, Oskadryl, Vidoran, Neodulax, Vidoran, Hemaviton, Neo Hormoviton, Polaris, Vitonal, Vitamin IPI, Neo rheumacyl Herbal, Wybert Herbal, Bodrexin Herbal, Herbalax, Marina, Natural Honey, Claudia, MY BABY, MY BABY Kids, Pure Baby, S.O.S, Total Care, and ULTIMA II brands. It also engages in the construction and rental of buildings; provision of warehousing, freight forwarding, advertising and promotion, research and development, and information technology and communication network systems services; and procurement, distribution, and marketing activities. The company was formerly known as PT Scanchemie. The company was founded in 1970 and is headquartered in Jakarta, Indonesia. PT Tempo Scan Pacific Tbk is a subsidiary of PT Bogamulia Nagadi.

Last 10 Buy Signals

Date Signal @
WNXMUSDMay 5 - 15:2567.21
STRKUSDMay 5 - 15:26$10.43
BGBUSDMay 5 - 15:251.169
ADFUSDMay 5 - 15:210.328
DIGGUSDMay 5 - 15:18731.51
MUSEUSDMay 5 - 15:1714.60
MOVRUSDMay 5 - 15:17$13.89
USDDUSDMay 5 - 15:120.996
LMWRUSDMay 5 - 15:111.057
LPTUSDMay 5 - 15:04$14.95

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.